Standardization and quality control studies of 'real-time'quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease …
J Gabert, E Beillard, VHJ Van der Velden, W Bi… - Leukemia, 2003 - nature.com
Detection of minimal residual disease (MRD) has proven to provide independent prognostic
information for treatment stratification in several types of leukemias such as childhood acute …
information for treatment stratification in several types of leukemias such as childhood acute …
Standardized definitions of molecular response in chronic myeloid leukemia
Abstract The International Randomized Study of Interferon and STI571 (IRIS) demonstrated
long-term cytogenetic responses in patients with chronic-phase chronic myeloid leukemia …
long-term cytogenetic responses in patients with chronic-phase chronic myeloid leukemia …
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR …
The introduction in 1998 of imatinib mesylate (IM) revolutionized management of patients
with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase …
with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase …
[HTML][HTML] Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes, J Kaeda, S Branford… - … England Journal of …, 2003 - Mass Medical Soc
Background In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in
chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy …
chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy …
Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time'quantitative reverse-transcriptase polymerase …
E Beillard, N Pallisgaard, VHJ Van der Velden, W Bi… - Leukemia, 2003 - nature.com
Real-time quantitative RT-PCR (RQ-PCR) is a sensitive tool to monitor minimal residual
disease (MRD) in leukemic patients through the amplification of a fusion gene (FG) …
disease (MRD) in leukemic patients through the amplification of a fusion gene (FG) …
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
BJ Druker, NB Lydon - The Journal of clinical investigation, 2000 - Am Soc Clin Investig
AProtein kinase targeted. A number of these molecules are broad-spectrum kinase
inhibitors. BStaurosporine class represents examples of broad-spectrum kinase inhibitors …
inhibitors. BStaurosporine class represents examples of broad-spectrum kinase inhibitors …
Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects
VHJ Van der Velden, A Hochhaus, G Cazzaniga… - Leukemia, 2003 - nature.com
Detection of minimal residual disease (MRD) has prognostic value in many hematologic
malignancies, including acute lymphoblastic leukemia, acute myeloid leukemia, chronic …
malignancies, including acute lymphoblastic leukemia, acute myeloid leukemia, chronic …
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate …
R Bhatia, M Holtz, N Niu, R Gray, DS Snyder… - Blood, 2003 - ashpublications.org
The BCR/ABL tyrosine kinase inhibitor imatinib mesylate (Gleevec, STI571; Novartis, Basel,
Switzerland) has shown remarkable efficacy in the treatment of chronic myelogenous …
Switzerland) has shown remarkable efficacy in the treatment of chronic myelogenous …
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in …
PD Kottaridis, RE Gale, SE Langabeer… - Blood, The Journal …, 2002 - ashpublications.org
FLT3 mutations, either internal tandem duplications (ITDs) or aspartate residue 835 (D835)
point mutations, are present in approximately one third of patients with acute myeloid …
point mutations, are present in approximately one third of patients with acute myeloid …
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia
H Kantarjian, M Talpaz, S O'Brien, G Garcia-Manero… - Blood, 2004 - ashpublications.org
Imatinib mesylate (STI571) is effective in chronic phase chronic myelogenous leukemia
(CML). However, most patients treated with 400 mg imatinib daily have variable levels of …
(CML). However, most patients treated with 400 mg imatinib daily have variable levels of …